TransThera Sciences (Nanjing), Inc. disclosed a best-effort placement of 3.84 million new H-shares at HK$40.83 each, representing an 18.01 % discount to the 18 May 2026 closing price of HK$49.80 and an 18.19 % discount to the five-day average of HK$49.91.
The proposed issuance equals 1.24 % of current H-shares and 0.95 % of total issued shares. Post-transaction, H-share capital would rise to 312.69 million, lifting the free float to 76.65 % while overall dilution is limited to 0.94 %.
Gross proceeds are expected to reach HK$156.62 million, with net proceeds of approximately HK$152.13 million after fees, implying a net issue price of HK$39.66 per share. Management plans to allocate about 90 % (HK$136.92 million) to develop additional indications for the company’s core oncology product Tinengotinib and 10 % (HK$15.21 million) to working capital and general corporate purposes.
The placement will be executed under the general mandate approved at the 4 August 2025 AGM, which originally authorised up to 79.38 million new shares. After two prior 2026 placements totalling 7.19 million shares, the mandate still permits issuance of up to 72.19 million shares, leaving substantial headroom post-transaction.
Completion is subject to customary conditions, including Hong Kong Stock Exchange listing approval and absence of termination events, with closing targeted for 27 May 2026. The company has agreed to a 30-day lock-up on further equity issuance.
This is TransThera’s third equity offering in 2026. Earlier placements in January and April raised HK$190.14 million and HK$282.15 million in net proceeds, respectively, primarily earmarked for Tinengotinib trials, pipeline R&D, manufacturing, and commercial build-out. Following the latest transaction, total gross equity capital raised in 2026 will approach HK$641.61 million.
TransThera positions the new funds as reinforcing liquidity, broadening the shareholder base, and supporting development and commercial readiness of its targeted therapies in oncology, inflammatory, and cardiometabolic diseases.